These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37903861)

  • 1. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.
    Wang DM; Chen DC; Xiu MH; Wang L; Kosten TR; Zhang XY
    Neuropsychopharmacology; 2024 Apr; 49(5):893-902. PubMed ID: 37903861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
    Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B
    Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study.
    Wu Z; Liu Q; Zhang Y; Guan X; Xiu M; Zhang X
    Int J Neuropsychopharmacol; 2022 Feb; 25(2):128-135. PubMed ID: 34622272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Cai DB; Yang XH; Ungvari GS; Ng CH; Müller N; Ning YP; Xiang YT
    J Psychiatr Res; 2017 Sep; 92():139-146. PubMed ID: 28445800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial.
    Zhu C; Guan X; Wang Y; Liu J; Kosten TR; Xiu M; Wu F; Zhang X
    Neurotherapeutics; 2022 Apr; 19(3):1037-1046. PubMed ID: 35467271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia.
    Qu M; Wang J; Chen DC; Chen S; Xiu MH; Zhang XY
    Free Radic Biol Med; 2020 Nov; 160():887-893. PubMed ID: 32949664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
    Müller N; Krause D; Dehning S; Musil R; Schennach-Wolff R; Obermeier M; Möller HJ; Klauss V; Schwarz MJ; Riedel M
    Schizophr Res; 2010 Aug; 121(1-3):118-24. PubMed ID: 20570110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
    Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ
    Am J Psychiatry; 2002 Jun; 159(6):1029-34. PubMed ID: 12042193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
    Zeinoddini A; Ahadi M; Farokhnia M; Rezaei F; Tabrizi M; Akhondzadeh S
    J Psychiatr Res; 2014 Dec; 59():125-31. PubMed ID: 25227564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
    Asadabadi M; Mohammadi MR; Ghanizadeh A; Modabbernia A; Ashrafi M; Hassanzadeh E; Forghani S; Akhondzadeh S
    Psychopharmacology (Berl); 2013 Jan; 225(1):51-9. PubMed ID: 22782459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics.
    Crisafulli C; Chiesa A; Han C; Lee SJ; Park MH; Balzarro B; Andrisano C; Patkar AA; Pae CU; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2012 Apr; 262(3):199-205. PubMed ID: 22120873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study.
    Wu ZW; Shi H; Chen DC; Chen S; Xiu MH; Zhang XY
    Psychoneuroendocrinology; 2020 Dec; 122():104879. PubMed ID: 33049658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.
    Zhu MH; Liu ZJ; Hu QY; Yang JY; Jin Y; Zhu N; Huang Y; Shi DH; Liu MJ; Tan HY; Zhao L; Lv QY; Yi ZH; Wu FC; Li ZZ
    Mil Med Res; 2022 Oct; 9(1):59. PubMed ID: 36253804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of COX-2 inhibitors on cognition in schizophrenia.
    Müller N; Riedel M; Schwarz MJ; Engel RR
    Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):149-51. PubMed ID: 15549344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.